BriaCell Therapeutics (BCTX) said late Tuesday it priced a public offering of 5.4 million units at $5.59 per unit for total expected gross proceeds of $30 million.
Each unit consists of one common share and one warrant to purchase common shares at $6.93 per share. The company may also issue, in lieu of common shares, pre-funded warrants.
Net proceeds will be used for working capital, general corporate purposes, and for the advancement of business objectives, BriaCell said.
Closing of the offering is expected to occur this Thursday, subject to customary closing conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments